Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial.
Bracarda
Sergio
S
Department of Oncology, Ospedale San Donato, Arezzo, Italy. sergio.bracarda@usl8.toscana.it
Bellmunt
Joaquim
J
Melichar
Bohuslav
B
Négrier
Sylvie
S
Bajetta
Emilio
E
Ravaud
Alain
A
Sneller
Vesna
V
Escudier
Bernard
B